Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH

Hamostaseologie. 2021 Jun;41(3):184-189. doi: 10.1055/a-1469-7481. Epub 2021 Apr 1.


The COVID-19 pandemic is an ongoing global healthcare crisis. Based on reports of atypically located thromboses following vaccination with the AstraZeneca COVID-19 vaccine, the Society of Thrombosis and Haemostasis Research (GTH) has issued guidance statements on the recognition, diagnosis, and treatment of this rare complication. It shares pathophysiological features with heparin-induced thrombocytopenia (HIT) and is referred to as vaccine-induced prothrombotic immune thrombocytopenia (VIPIT).

Die COVID-19 Pandemie stellt eine andauernde globale Gesundheitskrise dar. Basierend auf den Berichten über atypisch lokalisierte Thrombosen nach Impfung mit dem AstraZeneca COVID-19 Vakzin hat die Gesellschaft für Thrombose- und Hämostaseforschung (GTH) Handlungsempfehlungen zur Erkennung, Diagnostik und Therapie dieser seltenen Komplikation formuliert. Ihre Pathophysiologie ähnelt derjenigen der Heparin-induzierten Thrombozytopenie (HIT) und wird als Vakzin-induzierte prothrombotische Immunthrombozytopenie (VIPIT) bezeichnet.

MeSH terms

  • COVID-19 / pathology
  • COVID-19 / prevention & control*
  • COVID-19 / virology
  • COVID-19 Vaccines / administration & dosage
  • COVID-19 Vaccines / adverse effects*
  • Guidelines as Topic
  • Heparin / adverse effects
  • Humans
  • Purpura, Thrombocytopenic, Idiopathic / diagnosis
  • Purpura, Thrombocytopenic, Idiopathic / etiology
  • Risk Factors
  • SARS-CoV-2 / isolation & purification
  • Thrombosis / diagnosis*
  • Thrombosis / etiology


  • COVID-19 Vaccines
  • Heparin